Functional MRI and CT biomarkers in oncology

被引:0
作者
J. M. Winfield
G. S. Payne
N. M. deSouza
机构
[1] Institute of Cancer Research and Royal Marsden NHS Foundation Trust,CRUK Imaging Centre at the Institute of Cancer Research
[2] Institute of Cancer Research and Royal Marsden Hospital,MRI Unit
来源
European Journal of Nuclear Medicine and Molecular Imaging | 2015年 / 42卷
关键词
MRI; CT; Biomarker; Oncology;
D O I
暂无
中图分类号
学科分类号
摘要
Imaging biomarkers derived from MRI or CT describe functional properties of tumours and normal tissues. They are finding increasing numbers of applications in diagnosis, monitoring of response to treatment and assessment of progression or recurrence. Imaging biomarkers also provide scope for assessment of heterogeneity within and between lesions. A wide variety of functional parameters have been investigated for use as biomarkers in oncology. Some imaging techniques are used routinely in clinical applications while others are currently restricted to clinical trials or preclinical studies. Apparent diffusion coefficient, magnetization transfer ratio and native T1 relaxation time provide information about structure and organization of tissues. Vascular properties may be described using parameters derived from dynamic contrast-enhanced MRI, dynamic contrast-enhanced CT, transverse relaxation rate (R2*), vessel size index and relative blood volume, while magnetic resonance spectroscopy may be used to probe the metabolic profile of tumours. This review describes the mechanisms of contrast underpinning each technique and the technical requirements for robust and reproducible imaging. The current status of each biomarker is described in terms of its validation, qualification and clinical applications, followed by a discussion of the current limitations and future perspectives.
引用
收藏
页码:562 / 578
页数:16
相关论文
共 682 条
[71]  
Orsenigo E(2011)Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil J Hepatol 55 858-505
[72]  
Cellina M(2009)Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival Ann Oncol 20 1589-501
[73]  
Esposito A(2009)Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival Blood 113 3161-1441
[74]  
Agostini G(2009)Prognostic value of pre-treatment DCE-MRI parameters in predicting disease free and overall survival for breast cancer patients undergoing neoadjuvant chemotherapy Eur J Radiol 71 498-288
[75]  
Haradome H(2008)Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma Cancer Biol Ther 7 496-589
[76]  
Grazioli L(2012)Current status and guidelines for the assessment of tumour vascular support with dynamic contrast-enhanced computed tomography Eur Radiol 22 1430-628
[77]  
Morone M(2012)Reproducibility and comparison of DCE-MRI and DCE-CT perfusion parameters in a rat tumor model Technol Cancer Res Treat 11 279-2898
[78]  
Gambarini S(2013)Development of a dynamic quality assurance testing protocol for multisite clinical trial DCE-CT accreditation Med Phys 40 081906-332
[79]  
Kwee TC(2012)Operable non-small cell lung cancer: correlation of volumetric helical dynamic contrast-enhanced CT parameters with immunohistochemical markers of tumor hypoxia Radiology 264 581-5489
[80]  
Takahara T(2012)Angiogenesis of renal cell carcinoma: perfusion CT findings Abdom Imaging 35 622-S226